Intravesical BCG-Therapy for Superficial Bladder Cancer: Its Effectiveness and Adverse Effects

Summary: The aim of this investigation was to study the most significant complications of intravesical bacillus Calmette-Guérin (BCG) immunotherapy as well as the short-term effectiveness of the therapy on 174 patients with superficial transitional cell carcinoma of the bladder (Tis, Ta, or T1) treated in our hospitals. Six weekly instillations of 80 mg of BCG were given to 103 patients, six weekly and then four monthly instillations of the same dose to 55, and six weekly and then four monthly instillations of 40 mg to 16. The CR rate for Tis tumors was 79.2 % with those according to the treatment regimen being…